Targeting sites of damaged lung tissue using composition
The present invention relates to methods and compositions for targeting damaged lung tissue. Compositions provided feature a targeting moiety coupled to one or more other moieties, including, for example, a cross-linkable moiety, an imaging moiety, and/or one or more other targeting moieties. The methods and compositions of the invention find use, for example, in detecting and treating a pulmonary condition such as emphysema.
1 . A composition comprising a first targeting moiety and a second targeting moiety wherein said targeting moieties are coupled and wherein said targeting moieties target different sites of damaged lung tissue.
2 . The composition as recited in claim 1 wherein said lung tissue comprises epithelial lining fluid.
3 . The composition as recited in claim 1 wherein said different sites comprise different sites within an enlarged air space.
4 . The composition as recited in claim 1 wherein said first targeting moiety targets a first damage-correlated moiety and said second targeting moiety targets a second damage-correlated moiety, said first and second damage-correlated moieties occurring at said different sites.
5 . The composition as recited in claim 4 wherein said first and second damage-correlated moieties are the same.
6 . The composition as recited in claim 4 wherein said first and second damage-correlated moieties are different.
7 . The composition as recited in claim 1 wherein said targeting moieties are coupled via a chemical linker.
8 . The composition as recited in claim 7 wherein said chemical linker comprises two functional groups.
9 . The composition as recited in claim 8 wherein at least one of said functional groups is a hydroxyl group, a carboxyl group, an ester group, an amine group, or a lysine group.
10 . The composition as recited in claim 8 wherein at least one of said functional groups is a cyano group, a thiol group, a cysteine group, a carbonyl group, an aldehyde group, or a ketone group.
11 . The composition as recited in claim 1 wherein said targeting moieties are coupled as a fusion polypeptide.
12 . The composition as recited in claim 1 wherein said targeting moieties are coupled via a protein.
13 . The composition as recited in claim 1 wherein said targeting moieties are coupled via an antibody.
14 . The composition as recited in claim 1 wherein said composition does not comprise a polysaccharide or a carbohydrate moiety.
15 . The composition as recited in claim 1 wherein said composition does not comprise a mutant plasminogen activator-inhibitor type 1.
16 . The composition as recited in claim 1 wherein said first and/or second targeting moiety targets a damage-correlated moiety.
17 . The method as recited in claim 16 wherein said damage-correlated moiety comprises a cell surface marker.
18 . The method as recited in claim 16 wherein said damage-correlated moiety comprises an ECM component.
19 . The composition as recited in claim 1 wherein said first and/or second targeting moiety targets elastase.
20 . The composition as recited in claim 1 wherein said first and/or second targeting moiety targets neutropil elastase.
21 . The composition as recited in claim 1 wherein said first and/or second targeting moiety comprises a protease inhibitor moiety.
22 . The composition as recited in claim 1 wherein said first and/or second targeting moiety comprises an alpha-1 antitrypsin moiety.
23 . The composition as recited in claim 22 wherein said alpha-1 antitrypsin moiety is a recombinant alpha-1 antitrypsin moiety.
24 . The composition as recited in claim 1 wherein said first and/or second targeting moiety comprises an elafin moiety.
25 . The composition as recited in claim 24 wherein said elafin moiety is a recombinant elafin moiety.
26 . The composition as recited in claim 1 wherein said first and/or second targeting moiety comprises a serpin moiety.
27 . The composition as recited in claim 26 wherein said serpin moiety is a recombinant serpin moiety.
28 . The composition as recited in claim 26 wherein said serpin moiety is a secretory leukoprotease inhibitor (SLP1) moiety.
29 . The composition as recited in claim 28 wherein said secretory leukoprotease inhibitor (SLP1) moiety is a recombinant secretory leukoprotease inhibitor (SLP1) moiety.
30 . The composition as recited in claim 1 wherein said first and/or second targeting moiety targets at least one matrix metalloproteinase selected from MMP-1, MMP-2, MMP-3, MM-P4, MMP-5, MMP-6, MMP-7, MMP-8, and MMP-9.
31 . The composition as recited in claim 30 wherein said composition does not comprise a hyaluronic acid or a salt thereof.
32 . The composition as recited in claim 1 wherein said first and/or second targeting moiety targets desmosine and/or isodesmosine.
33 . The composition as recited in claim 1 wherein said first and/or second targeting moiety targets CD8 and/or CD4.
34 . The composition as recited in claim 1 wherein said first and/or second targeting moiety targets a smoke-related moiety.
35 . The composition as recited in claim 1 wherein said composition is less than 10 microns.
36 . The composition as recited in claim 1 wherein said composition is less than 5 microns.
37 . The composition as recited in claim 1 wherein said composition is less than 1 micron.
38 . The composition as recited in claim 1 wherein said composition further comprises a cross-linkable moiety coupled to said first and/or second targeting moieties.
39 . The composition as recited in claim 1 wherein said composition further comprises an imaging moiety coupled to said first and/or second targeting moieties.